Stock Events

Stock Events

Oculis 

$16
7
+$2.86+21.77% Wednesday 17:02

Statistics

Day High
16.65
Day Low
16
52W High
16.65
52W Low
16
Volume
340
Avg. Volume
-
Mkt Cap
894M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.78
-0.65
-0.53
-0.4
Expected EPS
-0.49970694738
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2023
2024
0Revenue
-191MNet Income

Analyst Ratings

$43.86Average Price Target
The highest estimate is 55.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCSAW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes with Oculis in the ophthalmology space, particularly in treatments for eye diseases like age-related macular degeneration.
Novartis
NVS
Mkt Cap237.61B
Novartis is a major player in the development of drugs for eye conditions, directly competing with Oculis in the ophthalmic drug market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has a strong presence in the eye care market, especially in treatments for conditions like dry eye, directly competing with Oculis.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is involved in gene therapy for ocular diseases, offering innovative treatments that compete with Oculis's drug development efforts.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, through its eye health division, competes in the same space as Oculis, particularly in treatments for eye diseases.
Rogers
ROG
Mkt Cap1.57B
Roche, with its ophthalmology division, competes in developing treatments for eye diseases, including macular degeneration and diabetic retinopathy, areas Oculis is also targeting.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has initiatives in developing treatments for eye conditions, potentially competing with Oculis in the broader ophthalmology market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca, through its acquisition of Alexion Pharmaceuticals, competes in the space of treatments for diseases including those affecting the eye, aligning as a competitor to Oculis.

About

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Show more...
CEO
Dr. Riad Sherif M.B.A., M.D.
Employees
49
Country
CH
ISIN
CH1246223429

Listings

XNAS
US
OCS
XNAS
US
OCSAW
F
DE
CR5.F
IC
IS
OCS.IC

0 Comments

Share your thoughts

FAQ

What is Oculis stock price today?▼
The current price of OCSAW is $16 USD — it has increased by +21.77% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.
What is Oculis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oculis stocks are traded under the ticker OCSAW.
Is Oculis stock price growing?▼
OCSAW stock has risen by +21.77% compared to the previous week, the month change is a -8.62% fall, over the last year Oculis has showed a +89.8% increase.
What is Oculis market cap?▼
Today Oculis has the market capitalization of 894M
When is the next Oculis earnings date?▼
Oculis is going to release the next earnings report on May 07, 2026.
What were Oculis earnings last quarter?▼
OCSAW earnings for the last quarter are -0.53 USD per share, whereas the estimation was -0.48 USD resulting in a -10.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oculis revenue for the last year?▼
Oculis revenue for the last year amounts to 0 USD.
What is Oculis net income for the last year?▼
OCSAW net income for the last year is -191M USD.
How many employees does Oculis have?▼
As of April 02, 2026, the company has 49 employees.
In which sector is Oculis located?▼
Oculis operates in the Health Care sector.
When did Oculis complete a stock split?▼
Oculis has not had any recent stock splits.
Where is Oculis headquartered?▼
Oculis is headquartered in Zug, CH.